# A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

Study · id `cardio:ct-nct02504294` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02504294](<https://clinicaltrials.gov/study/NCT02504294>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02504294

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 432 participants.

## Technical summary

Registry record NCT02504294. Randomized; no masking; primary purpose other. Start 2015-07-13 (actual); primary completion 2016-07-02 (actual). Results posted on 2018-06-13.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose other
- Phase: Phase 3
- Enrolled: 432 participants (enrolled count; ClinicalTrials.gov record NCT02504294, source copy `cardio:ctgov-nct02504294-2018-06-13`, retrieved 2026-10-26)
- Started: 2015-07-13 (actual) (ClinicalTrials.gov record NCT02504294, source copy `cardio:ctgov-nct02504294-2018-06-13`, retrieved 2026-10-26)
- Primary completion: 2016-07-02 (actual) (ClinicalTrials.gov record NCT02504294, source copy `cardio:ctgov-nct02504294-2018-06-13`, retrieved 2026-10-26)
- Completion: 2016-07-16 (actual) (ClinicalTrials.gov record NCT02504294, source copy `cardio:ctgov-nct02504294-2018-06-13`, retrieved 2026-10-26)
- Results first posted: 2018-06-13 (ClinicalTrials.gov record NCT02504294, source copy `cardio:ctgov-nct02504294-2018-06-13`, retrieved 2026-10-26)
- Countries: United States; Puerto Rico (ClinicalTrials.gov record NCT02504294, source copy `cardio:ctgov-nct02504294-2018-06-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02504294-2018-06-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
- Condition: Chronic Kidney Disease (CKD)
- Intervention (Biological): Epoetin Hospira Arm
- Intervention (Other): Standard of Care Arm
- Intervention (Drug): IV Iron
- Lead sponsor: Pfizer
- Lead sponsor class: INDUSTRY
- Collaborator: Hospira, now a wholly owned subsidiary of Pfizer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Pfizer (`cardio:org-pfizer`)
- Registry lists this organization as a collaborator: Hospira, now a wholly owned subsidiary of Pfizer (`cardio:org-hospira-now-a-wholly-owned-subsidiary-of-pfizer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis (`cardio:pubmed-30196301`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: dd64f1b13e31494742946221491bde88693627f278943456dceec7e86307d46f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
